Market Overview

UPDATE: Morgan Stanley Reiterates Overweight Rating, Raises PT on ResMed

Share:
Related RMD
11 Stocks Moving In Monday's After-Hours Session
Earnings Scheduled For January 22, 2018
ResMed's (RMD) CEO Mick Farrell on Q2 2018 Results - Earnings Call Transcript (Seeking Alpha)

In a report published Wednesday, Morgan Stanley reiterated its Overweight rating on ResMed (NYSE: RMD), and slightly raised its price target from $32.95 to $33.37.

Morgan Stanley noted, “While recovery in US device growth was observed, ROW device growth looked likely to continue deceleration from double-digit growth in FY11 to the low-single-digit growth reported in Q212 – the positive surprise of +7.0% in Q312 was impressive against the trend of ASP pressure in France and changes to PSG payment in Germany, and the stock is now priced for the positive level to continue.”

ResMed closed on Tuesday at $31.56.

Latest Ratings for RMD

DateFirmActionFromTo
Oct 2017JP MorganMaintainsOverweight
Oct 2017BMO CapitalMaintainsMarket Perform
Oct 2017BarclaysMaintainsUnderweight

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (RMD)

View Comments and Join the Discussion!